CL2015003683A1 -
Amorphous oral pharmaceutical formulation comprising the use of the formulation in the preparation of a medicament useful in the treatment and / or prophylaxis of diseases associated with the herpesviridae group, preferably associated with cytomegalovirus cmv amorphous letermovir preparation process.
- Google Patents
Amorphous oral pharmaceutical formulation comprising the use of the formulation in the preparation of a medicament useful in the treatment and / or prophylaxis of diseases associated with the herpesviridae group, preferably associated with cytomegalovirus cmv amorphous letermovir preparation process.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=65633011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015003683(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Anti Infective Cures GmbhfiledCriticalAicuris Anti Infective Cures Gmbh
Publication of CL2015003683A1publicationCriticalpatent/CL2015003683A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Abstract
Letermovir amorfo formulación oral farmacéutica que lo comprende uso de la formulación en la preparación de un medicamento útil en el tratamiento yo profilaxis de enfermedades asociadas con el grupo de Herpesviridae, preferiblemente asociadas con citomegalovirus CMV proceso de preparación de letermovir amorfo.Amorphous oral pharmaceutical formulation comprising the use of the formulation in the preparation of a medicament useful in the treatment and / or prophylaxis of diseases associated with the Herpesviridae group, preferably associated with CMV cytomegalovirus amorphous letermovir preparation process.
CL2015003683A2013-06-192015-12-18
Amorphous oral pharmaceutical formulation comprising the use of the formulation in the preparation of a medicament useful in the treatment and / or prophylaxis of diseases associated with the herpesviridae group, preferably associated with cytomegalovirus cmv amorphous letermovir preparation process.
CL2015003683A1
(en)
Amorphous oral pharmaceutical formulation comprising the use of the formulation in the preparation of a medicament useful in the treatment and / or prophylaxis of diseases associated with the herpesviridae group, preferably associated with cytomegalovirus cmv amorphous letermovir preparation process.
Pharmaceutical composition in the form of a tablet comprising atazanavir and cobicistat; preparation procedure; and use of the composition to prepare a medicament useful for treating human immunodeficiency virus (hiv) infection.
Amorphous oral pharmaceutical formulation comprising the use of the formulation in the preparation of a medicament useful in the treatment and / or prophylaxis of diseases associated with the herpesviridae group, preferably associated with cytomegalovirus cmv amorphous letermovir preparation process.
medicament, use of brexpiprazole or a pharmaceutically acceptable salt thereof, methods for preventing or treating a substance related disorder and for producing a pharmaceutical composition, pharmaceutical composition, and kit.